MedTrace Logo

Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

NCT05003037 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2026-07-08

No results posted yet for this study

Summary

A phase II study to assess the efficacy and safety of Surufatinib Combined With Toripalimab and Chemotherapy in patients with advanced non-squamous non-small cell lung cancer.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Surufatinib, Toripalimab, Pemetrexed, Carboplatin/Cisplatin

Surufatinib at the dose determined in phase safety lead-in, 250 mg, qd, po, every 3 weeks (q3w); Toripalimab at the dose 240mg, iv, d1, q3w; Pemetrexed at the dose 500 mg/m2, iv, d1, q3w; Carboplatin at the dose AUC=5\~6, iv, d1, q3w or Cisplatin at the dose 75 mg/m2, iv, d1, q3w; Maintenance treatment: After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D + Toripalimab 240mg, d1, q3w + Pemetrexed 500mg/m2, d1, q3w. Treatment continues until disease progression, death, or intolerable toxicity occurs.

Sponsors & Collaborators

  • Li Zhang, MD

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-06
Primary Completion
2025-11-03
Completion
2027-11-03

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05003037 on ClinicalTrials.gov